ImmunityBio, NantKwest announce positive interim phase 1 safety data of hAd5 Covid-19 vaccine dose study

ImmunityBio and NantKwest announce positive interim phase 1 safety data of hAd5 Covid-19 vaccine dose study. (Credit: Gerd Altmann from Pixabay)